The Mundipharma network of independent associated companies has a proud, 35-year heritage in pain management across Europe and is committed to enabling healthcare professionals to treat their patients in pain safely and responsibly. As a network that manufactures opioids, we believe we have a responsibility to take measures to minimize the risk of misuse and abuse of these medicines, while not depriving the patients that need them.
As a network, we recognize that misuse and abuse of pain medications can lead to addiction, overdose and death, and we are aware of the public health risk these potent medications can create, especially when they are diverted, misused and/or abused. That’s why we are committed to reducing the risk of misuse and abuse through a secure supply chain, appropriate education of healthcare professionals, responsible sales and marketing practices and close collaboration with government authorities and medical organizations.
We fund educational initiatives in line with industry regulations that clearly communicate the facts about opioid medicines in a balanced and responsible manner, outlining both risks and benefits and helping to ensure that our medicines are prescribed only to the right patient for the right reasons.
We are also committed to finding new approaches to the management of pain, including research into new mechanisms and medicines with the potential to reduce or avoid the need for opioids.
In Europe, heroin and opioid addiction is an emerging problem in our communities, and this population is often overlooked. We are encouraged that our medicines also play an important role in addiction rehabilitation treatment programs to help this underserved community.
Press return to search